TrialThe oncologist2021

Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.

Miao Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.